Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human CD14 Protein, Fc tag,100µg  

Recombinant human CD14 Protein, Fc tag,100µg

Recombinant Human CD14 Protein (Thr20-Cys352), produced in human 293 cells (HEK293), Fc tag (MALS verified)

Synonym
Recombinant Human Protein, CD14, CD-14

More details

CD4-H5252-100

Availability: within 7 days

312,00 €

Background
Cluster of differentiation 14 (CD14), is a cell surface glycoprotein, and is a is a component of the innate immune system. CD14 is a myelomonocytic differentiation antigen preferentially expressed on monocytes, macrophages, and activated granulocytes. CD14 exists in two forms. Either it is anchored into the membrane by a glycosylphosphatidylinositol tail (mCD14) or it appears in a soluble form (sCD14). Soluble CD14 either appears after shedding of mCD14 (48 kDa) or is directly secreted from intracellular vesicles (56 kDa).[1] CD14 acts as a co-receptor (along with the Toll-like receptor TLR 4 and MD-2) for the detection of bacterial lipopolysaccharide (LPS).[2-3] CD14 can bind LPS only in the presence of lipopolysaccharide-binding protein (LBP). CD14 has been proposed to be involved in various biological processes, including transportation of other lipids, cell-cell interaction during different immune responses, as well as recognition of apoptotic cells. Although LPS is considered its main ligand, CD14 also recognizes other pathogen-associated molecular patterns. CD14+ cells are monocytes that can differentiate into a host of different cells. CD14 has been shown to interact with Lipopolysaccharide-binding protein.[4- 5] 

Source
Recombinant Human CD14, Fc Tag (CD4-H5252) is expressed from human 293 cells (HEK293). It contains AA Thr 20 - Cys 352 (Accession # P08571-1).
Predicted N-terminus: Thr 20

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 62.2 kDa. The protein migrates as 75 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
N/A

Clinical and Translational Updates

(1) "Increased frequency of CD14+HLA-DR-/low cells in type 2 diabetes patients with poor glycemic control"
Valtierra-Alvarado, Castañeda-Delgado, Lugo-Villarino et al
Hum Immunol (2022)
(2) "SUPERVISED AND UNSUPERVISED LEARNING TO DEFINE THE CARDIOVASCULAR RISK OF PATIENTS ACCORDING TO AN EXTRACELLULAR VESICLE MOLECULAR SIGNATURE"
Burrello, Burrello, Vacchi et al
J Hypertens (2022) 40 (Suppl 1), e138
(3) "Melatonin protects sheep endometrial epithelial cells against lipopolysaccharide-induced inflammation in vitro"
Ge, Duan, Zeng et al
Reprod Domest Anim (2022)
Showing 1-3 of 28002 papers.